Lmv-12

MET Amplification

Hunan Province Tumor HospitalPhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the MET Amplification cohort.

Asset / Sponsor	Phase	Rating
Crizotinib Massachusetts General Hospital	Phase 2	BB
Osimertinib Qingdao Central Hospital	Phase 2	B
Carboplatin Guangdong Provincial People's Hospital	Phase 2	CCC
VOLITINIB Qingdao Central Hospital	Phase 2	CCC
Tepotinib Chungbuk National University Hospital	Phase 2	CCC

View all 10 →

Same molecule, other indications

Lmv-12 is also rated in:

EGF-R Positive Non-Small Cell Lung CancerDormant

CCC

Indicative ·

48 / 100

RET fusion positive cancerDormant

CCC

Indicative ·

48 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

41 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.